FDA proposes ban on bulk compounding of semaglutide and tirzepatide

• On April 30, 2026, the U.S. FDA announced it is considering removing GLP-1 medications from the 503B bulks list.
• FDA’s 503B bulks list identifies drug substances that outsourcing facilities can use to compound medications.
• Experts agree removing GLP-1s from the 503B bulks list will significantly lower the availability of compounded GLP-1s drugs.
• Patients may still be able to receive compounded GLP-1s through 503A compounding pharmacies, and consider legitimate alternatives for weight loss.

On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced it is considering removing glucagon-like peptide-1 (GLP-1) receptor agonists from the 503B bulks list, as there is no current clinical need for pharmacies to be able to compound these medications.

This could include drugs such as semaglutide (the active ingredient in Ozempic and Wegovy), tirzepatide (the active ingredient in Zepbound and Mounjaro), and liraglutide (the active ingredient in Victoza and Saxenda).

According to the FDA’s announcement, the organization is asking for submitted comments for or against this decision by the end of June 2026 before making their final determination.

Medical News Today spoke with 4 obesity experts to find out more about what the FDA’s 503B bulks list is, the potential future availability of compounded GLP-1 medications, and what alternatives may be available for users who may not be able to afford the brand name drugs.